Skip to main menu Skip to main content Skip to footer

Active Trials

Roche GR41987 RHONE-X

Posted by: Georgia Retina in

Research Title: A Study to Evaluate the Long-Term Safety and Tolerability of Faricimab in Participants With Diabetic Macular Edema (Rhone-X) Sponsor: Hoffmann-La Roche Principal Investigator: Robert A. Stoltz, MD, PhD Description: This is a multicenter long-term extension study designed to evaluate the long-term safety and tolerability of faricimab administered by intravitreal (IVT) injection at a personalized treatment interval (PTI)…

Read More

SamChungDang SCD411-CP101

Posted by: Georgia Retina in

Research Title: A Phase III Randomized, Double-Masked, Parallel Group, Multicenter Study to Compare the Efficacy, Safety, Tolerability, Pharmacokinetics, and Immunogenicity Between SCD411 and Eylea® in Subjects With Neovascular Age-related Macular Degeneration Sponsor: Sam Chung Dang Pharm. Co. Ltd. Principal Investigator: Robert A. Stoltz, MD, PhD Description: Age-related macular degeneration (AMD) is a leading cause of vision loss in adults….

Read More

Xbrane XBR1002 XPLORE

Posted by: Georgia Retina in

Research Title: A Phase III Double-Blind, Parallel Group, Multicenter Study to Compare the Efficacy and Safety of Xlucane Versus Lucentis® in Patients with Neovascular Age-Related Macular Degeneration (XPLORE). Sponsor: Xbrane BioPharma AB Principal Investigator: Atul Sharma, M.D. Description: The objectives of this study are to demonstrate the equivalence of Xlucane to Lucentis® in treatment of subjects with wet (i.e.,…

Read More

Roche GR40844 LUCERNE

Posted by: Georgia Retina in

Research Title: A Phase III, Multicenter, Randomized, Double-Masked, Active Comparator-Controlled Study to Evaluate the Efficacy and Safety of Faricimab in Patients with Neovascular Age-Related Macular Degeneration (LUCERNE) Sponsor: Genentech, Inc. / Hoffmann-La Roche Principal Investigator: Robert A. Stoltz, M.D., Ph.D. Description: This study will evaluate the efficacy, safety, durability, and pharmacokinetics of faricimab administered at intervals as specified in…

Read More

Roche GR41675 PAVILION

Posted by: Georgia Retina in

Research Title: A Phase III, Multicenter, Randomized Study of the Efficacy, Safety, and Pharmacokinetics of the Port Delivery System With Ranibizumab in Patients With Diabetic Retinopathy Sponsor: Hoffmann-La Roche Principal Investigator: Robert A. Stoltz, MD, PhD Description: Study GR41675 is a Multicenter, Randomized Study in Participants with Diabetic Retinopathy (DR) Without Center-Involved Diabetic Macular Edema (CI-DME) to Evaluate the…

Read More

Novartis CRTH258B2305 Kingfisher

Posted by: Georgia Retina in

Research Title: A 12-Month, 2-Arm, Randomized, Double-Masked, Multicenter Phase III Study Assessing the Efficacy and Safety of Brolucizumab vs. Aflibercept in Patients With Visual Impairment Due to Diabetic Macular Edema (KINGFISHER) Sponsor: Novartis Pharmaceuticals Principal Investigator: Robert Stoltz, M.D., Ph.D. Description: In this 12-month, randomized, double-masked,multicenter, active controlled study, consenting patients will be randomized in a 2:1 ratio (brolucizumab:…

Read More

Novo Nordisk NN9535-4352 FOCUS

Posted by: Georgia Retina in

Research Title: Long-term Effects of Semaglutide on Diabetic Retinopathy in Subjects With Type 2 Diabetes Sponsor: Novo Nordisk A/S Principal Investigator: Robert A. Stoltz, M.D., Ph.D. Description: This study will look at the long-term effects of semaglutide (active medicine) on diabetic eye disease when compared to placebo (dummy medicine). The study will be performed in people with type 2…

Read More

Roche GR40549 PORTAL

Posted by: Georgia Retina in

Research Title: A Multicenter, Open-Label Extension Study to Evaluate the Long-Term Safety and Tolerability of the Port Delivery System With Ranibizumab in Patients With Neovascular Age-Related Macular Degeneration Sponsor: Hoffmann-La Roche Principal Investigator: Robert A. Stoltz, MD, PhD Description: This study will evaluate the long-term safety and tolerability of the Port Delivery System with ranibizumab (PDS) 100 mg/mL with…

Read More

Roche GR40550 PAGODA

Posted by: Georgia Retina in

Research Title: A Phase III, Multicenter, Randomized, Visual Assessor-Masked, Active-comparator Study of the Efficacy, Safety, and Pharmacokinetics of the Port Delivery System With Ranibizumab in Patients with Diabetic Macular Edema (Pagoda) Sponsor: Hoffmann-La Roche Principal Investigator: Robert Stoltz, M.D., Ph.D. Description: This study will evaluate the efficacy, safety, and pharmacokinetics of the Port Delivery System with Ranibizumab (PDS) in…

Read More

Testimonials

What Our Patients Say

"I would first like to say, that it is a pleasure coming every month to get my eye injections solely based on the staff and my retina specialist! They are always so sweet, well educated, and very welcoming!"

- Hayley

"The staff is kind and very well informed. They walk you through exactly what is happening and give you all your options upfront (including financials). I would 100% recommend and I will be back for an annual checkup!"

- Pardis

"I have a great experience with Georgia Retina staff they make me feel right at home when I walk through the doors."

- Michael

"Dr. Stallman is an excellent physician. The staff in this office give excellent service extrodinar. They are all very kind, professional, and genuinely concerned about your care. Love these folks!"

- Vale

"Very few doctors today display the confidence in their ability that Dr Mukkamala has.  And does this without arrogance.  He explains a complicated procedure and is sure that you understand when he finishes.  I highly recommend him if you need this type of care."

- David

(888) 427-3846
Patient Portal
Refer a Patient